|
Strong Thalomid, Alkeran sales yield $0.03 earnings per share at biotech firm.
Publication: Biotech Business Week Publication Date: 18-AUG-03 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2003 NewsRX
2003 AUG 18 - (NewsRx.com & NewsRx.net) -- Celgene Corporation (CELG) announced earnings per diluted share of $0.03 driven by strong Thalomid (thalidomide) and Alkeran (melphalan) tablets and Alkeran (melphalan HCl) for injection sales.
Thalomid sales were approximately $54.8 million up 93.4% for the second quarter of 2003 compared to $28.3 million in the second quarter of 2002. Total revenue was $67.3 million, an increase of 100.1% over the prior-year quarter. Celgene posted net income of $2.9 million, or $0.03 per diluted share compared to a net loss of $1.7 million or ($0.02) per diluted share year-over-year.
Thalomid...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Biotech Business Week |
Vaccine maker reports net loss of $3.2M in second quarter.
August 18, 2003
|
Visx announces second quarter 2003 earnings results, appoints new pres...
August 18, 2003
|
Women's health revenues grow 58%.
August 18, 2003
|
Worldwide sales increase 1.6% for biotech firm.
August 18, 2003
|
System for whole human genome analysis uses single microarray.
August 18, 2003
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
